While the rest of us were at leisure, it’s been a busy time in European biotech, with a string of new company formations, funding rounds and licensing deals announced over the past five to six weeks.

These have ranged from big ticket partnerships like that between the Austrian antibody engineering specialist F-Star and pharma company Merck Serono which boasted a headline value of €492 million, to small financings such as the €2.5 million follow-on round announced by...

This page is available to Science|Business Network Members only. If you are already a member then please log in (above).

Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.

Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.

Be where innovation begins – become a member. Click here to learn more.